Physician profile
David A Dulitz
NPI 1073547592
$2,395.75
in general payments reported to CMS, 2019-2025
29 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $207 · 2021: $520 · 2022: $625 · 2023: $386 · 2024: $240 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817 · Education: $20.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.21 |
| Education | $20.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $844.30 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Genzyme Corporation | $178.05 | 2022-2025 | |
| Redhill Biopharma INC. | $155.84 | 2021-2023 | Talicia |
| Merck Sharp & Dohme LLC | $112.06 | 2020-2023 | Dificid |
| Celgene Corporation | $109.84 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $101.24 | 2020-2021 | |
| Ucb, INC. | $100.14 | 2019 | |
| Gilead Sciences, INC. | $90.13 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $73.79 | 2023-2025 | Voquezna |
| Boston Scientific Corporation | $73.17 | 2022-2023 | Captivator II |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.86 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.59 | 2023-2024 | Gattex, Eohilia, Entyvio |
| Nestle Healthcare Nutrition INC. | $62.16 | 2022 | |
| Allergan, INC. | $58.85 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $56.93 | 2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $46.90 | 2019-2023 | Sucraid |
| Janssen Biotech, INC. | $46.19 | 2021-2022 | |
| Evoke Pharma, INC. | $35.95 | 2020-2021 | |
| Novo Nordisk INC | $35.69 | 2025 | Wegovy |
| Conmed Corporation | $21.57 | 2024 | Conmed Dilation |
| Celltrion USA INC. | $20.79 | 2023 | Yuflyma |
| Shire North American Group INC | $18.32 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.39 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dulitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.